Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 69M | 101M | 84M | 73M | 62M |
| Gross Profit | 12M | 17M | 9M | 4M | -2M |
| Operating Income | -5M | 608K | -7M | -17M | -30M |
| EBITDA | -2M | 3M | -5M | -16M | -28M |
| Net Income | -5M | -480K | -8M | -19M | -33M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.62
+0.00% today
1Y Change
-26.44%
Window
Jun 23, 2025 → Jun 18, 2026
Coverage: 249 bars · Jun 23, 2025 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Rockwell Medical, Inc. (RMTI) is a Healthcare stock with a market cap of $30.00M and listed on NASDAQ. The stock last traded around $0.62 and down 26.4% across the available one-year price window (Jun 23, 2025 → Jun 18, 2026). Baseline metrics include revenue growth of -31.8%, EPS growth of -495.2%, a dividend yield of 0.0%. What stands out right now is revenue -31.8%, EPS -495.2%, free cash flow -137.6% with operating margin -6.8% and ROIC -9.5%. Valuation is more restrained than many high-expectation growth names at price/sales 0.5. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines RMTI price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
RMTI
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
RMTI Max Drawdown
-66.12%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for RMTI and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$61.9M
-14.9% YoY
FY Net Income
-$32.7M
-74.9% YoY
Free Cash Flow
-$34.1M
-97.9% YoY
Revenue Growth
-31.8%
EPS Growth
-495.2%
Gross Margin
16.9%
Net Margin
-7.7%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 69M | 101M | 84M | 73M | 62M |
| Gross Profit | 12M | 17M | 9M | 4M | -2M |
| Operating Income | -5M | 608K | -7M | -17M | -30M |
| EBITDA | -2M | 3M | -5M | -16M | -28M |
| Net Income | -5M | -480K | -8M | -19M | -33M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 25.0B | 16M | 9M | 10M | 13M |
| Total Assets | 57M | 59M | 52M | 47M | 49M |
| Total Liabilities | 20M | 27M | 31M | 33M | 46M |
| Shareholder Equity | 37M | 33M | 21M | 14M | 3M |
| Total Debt | 12M | 14M | 13M | 16M | 29M |
| Net Debt | -25.0B | -2M | 4M | 6M | 16M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
34M
-98.1% YoY
Capital Expenditures
522K
-85.8% YoY
Free Cash Flow
34M
-97.9% YoY
Key ratios
Gross Margin
16.9%
Operating Margin
-6.8%
Net Margin
-7.7%
ROE
-15.6%
Debt / Equity
0.34x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.